Emmes Announces Its Work on a Phase III Clinical Trial for Breakthrough Therapy Designation Product

Emmes announced that it provided the Phase III clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant.